|Articles|September 1, 2001

Depression and Generalized Anxiety Disorder: Managed Care Considerations
Volume 7
Issue 11 Suppl

Current Perspectives on the Diagnosis and Treatment of Major Depressive Disorder

Author(s)Andrew A. Nierenberg, MD

Download PDF: Current Perspectives on the Diagnosis and Treatment of Major Depressive Disorder

Articles in this issue

almost 25 years ago

Article

Participating Faculty

almost 25 years ago

Article

Introduction

almost 25 years ago

Article

Recent Perspectives on the Diagnosis and Treatment of Generalized Anxiety Disorder

almost 25 years ago

Article

The Clinical, Psychosocial, and Pharmacoeconomic Ramifications of Remission

almost 25 years ago

Article

The Pharmacoeconomics of Venlafaxine in Depression

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Current Perspectives on the Diagnosis and Treatment of Major Depressive Disorder

Articles in this issue

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Trending on AJMC

Jeff Hunnicutt to Bring Community Oncology Roots to New Role as Navista COO

Semaglutide More Than Doubled Likelihood of MASH Resolution

Once-Daily Pill Zasocitinib Clears Psoriasis at Toughest Sites

Delgocitinib Cream Projected to Save US Health Plans Millions for Chronic Hand Eczema

Contributor: How Health Systems Can Rebalance Behavioral Health Access